<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74040">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132143</url>
  </required_header>
  <id_info>
    <org_study_id>LH-2014-XW</org_study_id>
    <nct_id>NCT02132143</nct_id>
  </id_info>
  <brief_title>Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>People's Hospital of Guangxi</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study  compares   chemoradiation and sequential chemoradiation about
      Lung adenocarcinoma patients with postoperative in pN2 and then   determines  which
      therapeutic method is better for the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>two and a half years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>01/01/2014-06/01/2016</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>two and a half years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>01/01/2014-01/01-2016</description>
  </secondary_outcome>
  <other_outcome>
    <measure>side-effect</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>06/01/2014-06/01/2015</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Adenocarcinoma Patients With Postoperative in pN2</condition>
  <arm_group>
    <arm_group_label>Progression-free survival&amp;Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy,  21 days as a cycle.
Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progression-free survival&amp;sequential chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2,  21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation</intervention_name>
    <description>For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.</description>
    <arm_group_label>Progression-free survival&amp;Concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation</intervention_name>
    <description>For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.</description>
    <arm_group_label>Progression-free survival&amp;sequential chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Lung adenocarcinoma

          -  Postoperative staging pN2 period

          -  Voluntary participation and informed consent

          -  Age ≥ 18 years old, male or female, within six months of weight loss of less
               than 10%, can tolerate radiotherapy

          -  performance status( PS) score 0-2.

          -  Hemoglobin ≥ 80 g / L, white blood cell  ≥ 4 × 109 / L, platelets ≥ 100 × 109 / L.

          -  Liver function: alanine aminotransferase (ALAT), aspartate transaminase (ASAT) &lt;upper
             limit of normal (ULN) of 1.5 times, bilirubin &lt;1.5 × ULN.

          -  Renal function: serum creatinine &lt;1.5 × ULN.

          -  Compliance, and can be regular follow-up, voluntary compliance with study
             requirements

        Exclusion Criteria:

          -  Do not meet the inclusion criteria

          -  There is evidence of distant metastases

          -  Suffered from other malignancies in five years

          -  Within the past January subjects received other drug trials

          -  Having serious allergies or idiosyncratic persons, such as you can not use folic
             acid, dexamethasone, vitamin B12 patients

          -  Severe lung or heart disease, a history

          -  Refuses or is unable to sign informed consent to participate in trials

          -  The abuse of drugs or alcohol addicts.

          -  Patients with difficult to control bacterial, viral, fungal infections

          -  Having a personality or mental disorders, without civil capacity or restricted civil
             capacity.

          -  Being pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Lin, Doctor</last_name>
    <phone>8613878133622</phone>
    <email>linhui33266@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiao Yang, Master</last_name>
    <phone>8613707872959</phone>
    <email>yyvsyy6912@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning Shi</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Lin</last_name>
      <phone>8613878133266</phone>
      <email>linhui33266@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>People's Hospital of Guangxi</investigator_affiliation>
    <investigator_full_name>Hui Lin</investigator_full_name>
    <investigator_title>The president of the People's Hospital of Guangxi</investigator_title>
  </responsible_party>
  <keyword>Lung adenocarcinoma</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <keyword>Sequential chemoradiotherapy</keyword>
  <keyword>Progression-free survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
